Evidence Level
Colostrum is a nutrient-rich milk produced by mammals immediately after birth, with bovine colostrum being a common source for human supplementation. It contains immunoglobulins, growth factors, and other bioactive compounds that support immune function and gut health. Research indicates that bovine colostrum has moderate clinical evidence for gut barrier support, particularly in reducing exercise-related gut permeability (Marchbank et al., 2011). Additionally, it has been shown to mitigate the increase in intestinal permeability caused by non-steroidal anti-inflammatory drugs (NSAIDs) (Playford et al., 2001).
Recent studies have highlighted the potential benefits of colostrum in neonatal care. A systematic review and meta-analysis of 21 studies involving 2393 preterm neonates found that oropharyngeal colostrum therapy significantly reduces culture-proven sepsis (RR: 0.78, 95% CI: 0.65-0.94) with high certainty of evidence (Anne et al., 2024). Similarly, a meta-analysis of 17 RCTs involving 4106 preterm infants demonstrated that oropharyngeal application of colostrum/mother's milk reduces sepsis, necrotizing enterocolitis (NEC), and accelerates enteral feeding initiation (Kumar et al., 2023).
Despite these benefits, limitations remain. Small study sizes, variability in product quality, and the insufficient survival of IgG through gastric transit for systemic immunity are notable concerns. Furthermore, heat treatment of colostrum can reduce immunoglobulin concentrations, although this may increase serum immunoglobulins (Malik et al., 2022). Overall, while colostrum shows promise in gut barrier protection and neonatal care, further research is needed to address these limitations and optimize its therapeutic applications.